Biotech Values

[jq1234]

Well, you are not adding any new information to the discussion at this point. Until then, there isn't much to discuss further. I have to give you credit for at least not insisting CRs beyond morphological and molecular remission as both the title and body of abstract stated clearly.

You can add another 100 maybes to why the company does nothing but burning money for one year, it still doesn't make any sense. It is truly one of its kind. Maybe that will be the catalyst to become the next PCYC, or even CELG!